Bioengineering Strategies for Designing Targeted Cancer Therapies

被引:76
作者
Alexander-Bryant, Angela A. [1 ,2 ]
Vanden Berg-Foels, Wendy S. [1 ,2 ,3 ]
Wen, Xuejun [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构
[1] Clemson Univ, Dept Bioengn, Clemson, SC 29631 USA
[2] Med Univ S Carolina, Dept Craniofacial Biol, Charleston, SC 29425 USA
[3] Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, Richmond, VA USA
[4] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA
[5] Med Univ S Carolina, Dept Orthoped Surg, Charleston, SC 29425 USA
[6] Tongji Univ, Sch Med, Inst Biomed Engn & Nanotechnol, Shanghai 200092, Peoples R China
[7] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
[8] Med Univ S Carolina, Coll Dent Med, Charleston, SC 29425 USA
来源
ADVANCES IN CANCER RESEARCH, VOL 118 | 2013年 / 118卷
关键词
ENDOTHELIAL GROWTH-FACTOR; POLY(BETA-AMINO ESTER) NANOPARTICLES; BIODEGRADABLE POLYMERIC MICELLES; PACLITAXEL-LOADED NANOPARTICLES; WALLED CARBON NANOTUBES; ENZYME PRODRUG THERAPY; PH-SENSITIVE SYSTEM; BLOOD-BRAIN-BARRIER; DRUG-DELIVERY; IN-VITRO;
D O I
10.1016/B978-0-12-407173-5.00002-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The goals of bioengineering strategies for targeted cancer therapies are (1) to deliver a high dose of an anticancer drug directly to a cancer tumor, (2) to enhance drug uptake by malignant cells, and (3) to minimize drug uptake by nonmalignant cells. Effective cancer-targeting therapies will require both passive- and active-targeting strategies and a thorough understanding of physiologic barriers to targeted drug delivery. Designing a targeted therapy includes the selection and optimization of a nanoparticle delivery vehicle for passive accumulation in tumors, a targeting moiety for active receptor-mediated uptake, and stimuli-responsive polymers for control of drug release. The future direction of cancer targeting is a combinatorial approach, in which targeting therapies are designed to use multiple-targeting strategies. The combinatorial approach will enable combination therapy for delivery of multiple drugs and dual ligand targeting to improve targeting specificity. Targeted cancer treatments in development and the new combinatorial approaches show promise for improving targeted anticancer drug delivery and improving treatment outcomes.
引用
收藏
页码:1 / 59
页数:59
相关论文
共 303 条
[1]
ACS, 2012, CANC FACTS FIG 2012
[2]
Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
[3]
Alexis Frank, 2010, Handb Exp Pharmacol, P55, DOI 10.1007/978-3-642-00477-3_2
[4]
Ali HM, 2012, EXPERT REV CLIN PHAR, V5, P403, DOI [10.1586/ECP.12.33, 10.1586/ecp.12.33]
[5]
Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[6]
In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer [J].
Anabousi, Samah ;
Bakowsky, Udo ;
Schneider, Marc ;
Huwer, Hanno ;
Lehr, Claus-Michael ;
Ehrhardt, Carsten .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 29 (05) :367-374
[7]
[Anonymous], 2008, MEDICINE
[8]
Arias JL, 2011, MINI-REV MED CHEM, V11, P1
[9]
Nanoparticle-Mediated Delivery of Anticancer Agents to Tumor Angiogenic Vessels [J].
Asai, Tomohiro .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2012, 35 (11) :1855-1861
[10]
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature [J].
Backer, MV ;
Gaynutdinov, TI ;
Patel, V ;
Bandyopadhyaya, AK ;
Thirumamagal, BTS ;
Tjarks, W ;
Barth, RF ;
Claffey, K ;
Backer, JM .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (09) :1423-1429